Anticancer Drugs Market Segmented By Cytotoxic, Hormonal Therapy, Monoclonal antibodies, Small molecule inhibitors as Targeted Therapy in Hospital Pharmacies and Retail Pharmacies
Report ID: PMRREP24355
Number of Pages: 274
Format: PPT*, PDF, EXCEL
Industry: Healthcare
Published Date: September-2018
1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. PMR Analysis and Recommendations
1.4. Wheel of Fortune
2. Market Introduction
2.1. Market Definition
2.2. Market Taxonomy
3. Anti-Cancer Drugs Market Opportunity Analysis
3.1. Macro-Economic Factors
3.2. Opportunity Analysis
4. Market Background
4.1. Recent Developments
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Trends
4.3. Reimbursement Landscape
4.4. Regulatory Scenario
5. Macroeconomic Assumptions
6. Global Economic Outlook
6.1. Gross Domestic Product by Region & Country, 2006 – 2021
6.2. Disease Outlook
7. Key Inclusions
7.1. Epidemiology
7.2. Pipeline Analysis
7.3. Mergers and Acquisitions
8. North America Anti-Cancer Drugs Market Analysis 2012–2016 and Forecast 2017–2025
8.1. Introduction
8.2. Historical Market Value (US$ Mn) Analysis By Country, 2012–2016
8.2.1. U.S.
8.2.2. Canada
8.3. Market Value (US$ Mn) Forecast By Country, 2017–2025
8.4. Historical Market Value (US$ Mn) Trend Analysis By Drug Class, 2012–2016
8.4.1. Cytotoxics
8.4.2. Hormonal Therapy
8.4.3. Targeted Therapy
8.4.3.1. Monoclonal antibodies
8.4.3.2. Small molecule inhibitors
8.5. Market Value (US$ Mn) Forecast By Drug Class, 2017–2025
8.6. Historical Market Value (US$ Mn) Trend Analysis By Indications, 2012–2016
8.6.1. Prostate Cancer
8.6.2. Lung Cancer
8.6.3. Breast Cancer
8.6.4. Melanoma
8.6.5. Leukemia
8.6.6. Others
8.7. Market Value (US$ Mn) Forecast By Indications, 2017–2025
8.8. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channels, 2012–2016
8.8.1. Hospital Pharmacies
8.8.2. Retail Pharmacies
8.9. Market Value (US$ Mn) Forecast By Distribution Channels, 2017–2025
8.10. Market Attractiveness Analysis
8.10.1. By Country
8.10.2. By Drug Class
8.10.3. By Indications
8.10.4. By Distribution Channels
8.11. Key Market Participants – Intensity Mapping
8.12. Drivers and Restraints – Impact Analysis
9. Latin America Anti-Cancer Drugs Market Analysis 2012–2016 and Forecast 2017–2025
9.1. Introduction
9.2. Historical Market Value (US$ Mn) Trends Analysis By Country, 2012–2016
9.2.1. Brazil
9.2.2. Mexico
9.2.3. Rest of Latin America
9.3. Market Value (US$ Mn) Forecast By Country, 2017–2025
9.4. Historical Market Value (US$ Mn) Trend Analysis By Drug Class, 2012–2016
9.4.1. Cytotoxics
9.4.2. Hormonal Therapy
9.4.3. Targeted Therapy
9.4.3.1. Monoclonal antibodies
9.4.3.2. Small molecule inhibitors
9.5. Market Value (US$ Mn) Forecast By Drug Class, 2017–2025
9.6. Historical Market Value (US$ Mn) Trend Analysis By Indications, 2012–2016
9.6.1. Prostate Cancer
9.6.2. Lung Cancer
9.6.3. Breast Cancer
9.6.4. Melanoma
9.6.5. Leukemia
9.6.6. Others
9.7. Market Value (US$ Mn) Forecast By Indications, 2017–2025
9.8. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channels, 2012–2016
9.8.1. Hospital Pharmacies
9.8.2. Retail Pharmacies
9.9. Market Value (US$ Mn) Forecast By Distribution Channels, 2017–2025
9.10. Market Attractiveness Analysis
9.10.1. By Country
9.10.2. By Drug Class
9.10.3. By Indications
9.10.4. By Distribution Channels
9.11. Key Market Participants – Intensity Mapping
9.12. Drivers and Restraints – Impact Analysis
10. Europe Anti-Cancer Drugs Market Analysis 2012–2016 and Forecast 2017–2025
10.1. Introduction
10.2. Historical Market Value (US$ Mn) Trend Analysis By Country, 2012–2016
10.2.1. Germany
10.2.2. U.K.
10.2.3. France
10.2.4. Italy
10.2.5. Spain
10.2.6. Russia
10.2.7. Rest of Europe
10.3. Market Value (US$ Mn) Forecast By Country, 2017–2025
10.4. Historical Market Value (US$ Mn) Trend Analysis By Drug Class, 2012–2016
10.4.1. Cytotoxics
10.4.2. Hormonal Therapy
10.4.3. Targeted Therapy
10.4.3.1. Monoclonal antibodies
10.4.3.2. Small molecule inhibitors
10.5. Market Value (US$ Mn) Forecast By Drug Class, 2017–2025
10.6. Historical Market Value (US$ Mn) Trend Analysis By Indications, 2012–2016
10.6.1. Prostate Cancer
10.6.2. Lung Cancer
10.6.3. Breast Cancer
10.6.4. Melanoma
10.6.5. Leukemia
10.6.6. Others
10.7. Market Value (US$ Mn) Forecast By Indications, 2017–2025
10.8. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channels, 2012–2016
10.8.1. Hospital Pharmacies
10.8.2. Retail Pharmacies
10.9. Market Value (US$ Mn) Forecast By Distribution Channels, 2017–2025
10.10. Market Attractiveness Analysis
10.10.1. By Country
10.10.2. By Drug Class
10.10.3. By Indications
10.10.4. By Distribution Channels
10.11. Key Market Participants – Intensity Mapping
10.12. Drivers and Restraints – Impact Analysis
11. Asia Pacific Anti-Cancer Drugs Market Analysis 2012–2016 and Forecast 2017–2025
11.1. Introduction
11.2. Historical Market Value (US$ Mn) Trend Analysis By Country, 2012–2016
11.2.1. China
11.2.2. India
11.2.3. Australia and NZ
11.2.4. ASEAN
11.2.5. Rest of Asia Pacific
11.3. Market Value (US$ Mn) Forecast By Country, 2017–2025
11.4. Historical Market Value (US$ Mn) Trend Analysis By Drug Class, 2012–2016
11.4.1. Cytotoxics
11.4.2. Hormonal Therapy
11.4.3. Targeted Therapy
11.4.3.1. Monoclonal antibodies
11.4.3.2. Small molecule inhibitors
11.5. Market Value (US$ Mn) Forecast By Drug Class, 2017–2025
11.6. Historical Market Value (US$ Mn) Trend Analysis By Indications, 2012–2016
11.6.1. Prostate Cancer
11.6.2. Lung Cancer
11.6.3. Breast Cancer
11.6.4. Melanoma
11.6.5. Leukemia
11.6.6. Others
11.7. Market Value (US$ Mn) Forecast By Indications, 2017–2025
11.8. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channels, 2012–2016
11.8.1. Hospital Pharmacies
11.8.2. Retail Pharmacies
11.9. Market Value (US$ Mn) Forecast By Distribution Channels, 2017–2025
11.10. Market Attractiveness Analysis
11.10.1. By Country
11.10.2. By Drug Class
11.10.3. By Indications
11.10.4. By Distribution Channels
11.11. Key Market Participants – Intensity Mapping
11.12. Drivers and Restraints – Impact Analysis
12. Japan Anti-Cancer Drugs Market Analysis 2012–2016 and Forecast 2017–2025
12.1. Introduction
12.2. Historical Market Value (US$ Mn) Trend Analysis By Drug Class, 2012–2016
12.2.1. Cytotoxics
12.2.2. Hormonal Therapy
12.2.3. Targeted Therapy
12.2.3.1. Monoclonal antibodies
12.2.3.2. Small molecule inhibitors
12.3. Market Value (US$ Mn) Forecast By Drug Class, 2017–2025
12.4. Historical Market Value (US$ Mn) Trend Analysis By Indications, 2012–2016
12.4.1. Prostate Cancer
12.4.2. Lung Cancer
12.4.3. Breast Cancer
12.4.4. Melanoma
12.4.5. Leukemia
12.4.6. Others
12.5. Market Value (US$ Mn) Forecast By Indications, 2017–2025
12.6. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channels, 2012–2016
12.6.1. Hospital Pharmacies
12.6.2. Retail Pharmacies
12.7. Market Value (US$ Mn) Forecast By Distribution Channels, 2017–2025
12.8. Market Attractiveness Analysis
12.8.1. By Drug Class
12.8.2. By Indications
12.8.3. By Distribution Channels
12.9. Key Market Participants – Intensity Mapping
12.10. Drivers and Restraints – Impact Analysis
13. Middle East & Africa Anti-Cancer Drugs Market Analysis 2012–2016 and Forecast 2017–2025
13.1. Introduction
13.2. Historical Market Value (US$ Mn) Trend Analysis By Country, 2012–2016
13.2.1. South Africa
13.2.2. GCC Countries
13.2.3. Rest of MEA
13.3. Market Value (US$ Mn) Forecast By Country, 2017–2025
13.4. Historical Market Value (US$ Mn) Trend Analysis By Drug Class, 2012–2016
13.4.1. Cytotoxics
13.4.2. Hormonal Therapy
13.4.3. Targeted Therapy
13.4.3.1. Monoclonal antibodies
13.4.3.2. Small molecule inhibitors
13.5. Market Value (US$ Mn) Forecast By Drug Class, 2017–2025
13.6. Historical Market Value (US$ Mn) Trend Analysis By Indications, 2012–2016
13.6.1. Prostate Cancer
13.6.2. Lung Cancer
13.6.3. Breast Cancer
13.6.4. Melanoma
13.6.5. Leukemia
13.6.6. Others
13.7. Market Value (US$ Mn) Forecast By Indications, 2017–2025
13.8. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channels, 2012–2016
13.8.1. Hospital Pharmacies
13.8.2. Retail Pharmacies
13.9. Market Value (US$ Mn) Forecast By Distribution Channels, 2017–2025
13.10. Market Attractiveness Analysis
13.10.1. By Country
13.10.2. By Drug Class
13.10.3. By Indications
13.10.4. By Distribution Channels
13.11. Key Market Participants – Intensity Mapping
13.12. Drivers and Restraints – Impact Analysis
14. Forecast Factors: Relevance and Impact
15. Forecast Assumptions
16. Competition Analysis
16.1. Competition Dashboard
16.2. Company Deep Dive
16.2.1. F. Hoffmann-La Roche Ltd
16.2.1.1. Overview
16.2.1.2. Product and Indications Portfolio
16.2.1.3. Production Footprint
16.2.1.4. Sales Footprint
16.2.1.5. Channel Footprint
16.2.1.6. Strategy
16.2.1.6.1. Marketing Strategy
16.2.1.6.2. Product Strategy
16.2.1.6.3. Channel Strategy
16.2.2. Celgene Corp
16.2.2.1. Overview
16.2.2.2. Product and Indications Portfolio
16.2.2.3. Production Footprint
16.2.2.4. Sales Footprint
16.2.2.5. Channel Footprint
16.2.2.6. Strategy
16.2.2.6.1. Marketing Strategy
16.2.2.6.2. Product Strategy
16.2.2.6.3. Channel Strategy
16.2.3. Novartis AG
16.2.3.1. Overview
16.2.3.2. Product and Indications Portfolio
16.2.3.3. Production Footprint
16.2.3.4. Sales Footprint
16.2.3.5. Channel Footprint
16.2.3.6. Strategy
16.2.3.6.1. Marketing Strategy
16.2.3.6.2. Product Strategy
16.2.3.6.3. Channel Strategy
16.2.4. Bristol-Myers Squibb Co
16.2.4.1. Overview
16.2.4.2. Product and Indications Portfolio
16.2.4.3. Production Footprint
16.2.4.4. Sales Footprint
16.2.4.5. Channel Footprint
16.2.4.6. Strategy
16.2.4.6.1. Marketing Strategy
16.2.4.6.2. Product Strategy
16.2.4.6.3. Channel Strategy
16.2.5. Johnson & Johnson
16.2.5.1. Overview
16.2.5.2. Product and Indications Portfolio
16.2.5.3. Production Footprint
16.2.5.4. Sales Footprint
16.2.5.5. Channel Footprint
16.2.5.6. Strategy
16.2.5.6.1. Marketing Strategy
16.2.5.6.2. Product Strategy
16.2.5.6.3. Channel Strategy
16.2.6. Merck & Co.
16.2.6.1. Overview
16.2.6.2. Product and Indications Portfolio
16.2.6.3. Production Footprint
16.2.6.4. Sales Footprint
16.2.6.5. Channel Footprint
16.2.6.6. Strategy
16.2.6.6.1. Marketing Strategy
16.2.6.6.2. Product Strategy
16.2.6.6.3. Channel Strategy
16.2.7. Eli Lilly and Company
16.2.7.1. Overview
16.2.7.2. Product and Indications Portfolio
16.2.7.3. Production Footprint
16.2.7.4. Sales Footprint
16.2.7.5. Channel Footprint
16.2.7.6. Strategy
16.2.7.6.1. Marketing Strategy
16.2.7.6.2. Product Strategy
16.2.7.6.3. Channel Strategy
16.2.8. AstraZeneca plc
16.2.8.1. Overview
16.2.8.2. Product and Indications Portfolio
16.2.8.3. Production Footprint
16.2.8.4. Sales Footprint
16.2.8.5. Channel Footprint
16.2.8.6. Strategy
16.2.8.6.1. Marketing Strategy
16.2.8.6.2. Product Strategy
16.2.8.6.3. Channel Strategy
16.2.9. Amgen Inc..
16.2.9.1. Overview
16.2.9.2. Product and Indications Portfolio
16.2.9.3. Production Footprint
16.2.9.4. Sales Footprint
16.2.9.5. Channel Footprint
16.2.9.6. Strategy
16.2.9.6.1. Marketing Strategy
16.2.9.6.2. Product Strategy
16.2.9.6.3. Channel Strategy
16.2.10. Roche Holding AG
16.2.10.1. Overview
16.2.10.2. Product and Indications Portfolio
16.2.10.3. Production Footprint
16.2.10.4. Sales Footprint
16.2.10.5. Channel Footprint
16.2.10.6. Strategy
16.2.10.6.1. Marketing Strategy
16.2.10.6.2. Product Strategy
16.2.10.6.3. Channel Strategy
17. Global Anti-Cancer Drugs Market Analysis 2012–2016 and Forecast 2017–2025, By Region
17.1. Introduction/Key Findings
17.2. Historical Market Value (US$ Mn) Trend Analysis By Region, 2012–2016
17.3. Market Value (US$ Mn) Forecast By Region, 2017–2025
17.3.1. North America
17.3.2. Latin America
17.3.3. Europe
17.3.4. Asia Pacific
17.3.5. Middle East & Africa
17.3.6. China
17.4. Market Attractiveness Analysis By Region
18. Global Anti-Cancer Drugs Analysis 2012–2016 and Forecast 2017–2025, By Drug Class
18.1. Introduction/Key Findings
18.2. Historical Market Value (US$ Mn) Trend Analysis By Drug Class, 2012–2016
18.2.1. Cytotoxics
18.2.2. Hormonal Therapy
18.2.3. Targeted Therapy
18.2.3.1. Monoclonal antibodies
18.2.3.2. Small molecule inhibitors
18.3. Market Value (US$ Mn) Forecast By Drug Class, 2017–2025
18.4. Market Attractiveness Analysis
19. Global Anti-Cancer Drugs Market Analysis 2012–2016 and Forecast 2017–2025, By Indications
19.1. Introduction/Key Findings
19.2. Historical Market Value (US$ Mn) Trend Analysis By Indications, 2012–2016
19.2.1. Prostate Cancer
19.2.2. Lung Cancer
19.2.3. Breast Cancer
19.2.4. Melanoma
19.2.5. Leukemia
19.2.6. Others
19.3. Market Value (US$ Mn) Forecast By Indications, 2017–2025
19.4. Market Attractiveness Analysis By Indications
20. Global Anti-cancer Drugs Market Analysis 2012–2016 and Forecast 2017–2025, By Distribution Channels
20.1. Introduction/Key Findings
20.2. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channels, 2012–2016
20.2.1. Hospital Pharmacies
20.2.2. Retail Pharmacies
20.3. Market Value (US$ Mn) Forecast By Distribution Channels, 2017–2025
20.4. Market Attractiveness Analysis By Distribution Channels
21. Global Anti-Cancer Drugs Market Analysis 2012–2016 and Forecast 2017–2025
21.1. Market Value Share Analysis By All Segment
21.2. Y-o-Y Growth Analysis By All Segment
21.3. Absolute $ Opportunity
22. Research Methodology
Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
Table 01A: Funding by Research Areas 2017 (US $Millions)
Table 01A: Funding by Research Areas 2017 (US $Millions)
Table 01B: Funding by Research Areas 2017 (US $Millions)
Table 02A: New Active Substances Launched in 2017 and Summary of Clinical Benefits
Table 02B: New Active Substances Launched in 2017 and Summary of Clinical Benefits
Table 02C: New Active Substances Launched in 2017 and Summary of Clinical Benefits
Table 03: Estimated Number of Deaths for the Four Major Cancers by Sex and Age Group, 2017
Table 04: Estimated New Cases for the Four Major Cancers by Sex and Age Group, 2016
Table 05: Difference in approval times between EMEA and FDA for selected targeted therapies
Table 06: Expenditure on Health, (% of GDP), by Country, 2016 - 2021
Table 07: Expenditure on Health, (% of GDP), by Country, 2016 - 2021
Table 8A: Prevalence of Cancer in North America, 2017
Table 8B: Prevalence of Cancer in Latin America, 2017
Table 8C: Prevalence of Cancer in Asia Pacific, 2017
Table 8D: Prevalence of Cancer in Europe, 2017
Table 09: Number of FDA Approvals (2010-2017)
Table 10: North America Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 11: North America Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
Table 12: North America Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indication
Table 13: North America Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
Table 14: North America Anticancer Drugs Market Participants Presence (Intensity Mapping)
Table 15: Latin America Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 16: Latin America Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
Table 17: Latin America Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indication
Table 18: Latin America Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
Table 19: North America Anticancer Drugs Market Participants Presence (Intensity Mapping)
Table 20: Europe Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 21: Europe Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
Table 22: Europe Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indication
Table 23: Europe Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
Table 24: Europe Anticancer Drugs Market Participants Presence (Intensity Mapping)
Table 25: Asia Pacific Excluding Japan Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 26: Asia Pacific Excluding Japan Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
Table 27: Asia Pacific Excluding Japan Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indication
Table 28: Asia Pacific Excluding Japan Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
Table 29: Asia Pacific Excluding Japan Anticancer Drugs Market Participants Presence (Intensity Mapping)
Table 30: Japan Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
Table 31: Japan Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indication
Table 32: Japan Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
Table 33: Japan Anticancer Drugs Market Participants Presence (Intensity Mapping)
Table 34: Middle East and Africa Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
Table 35: Middle East and Africa Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
Table 36: Middle East and Africa Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indication
Table 37: Middle East and Africa Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
Table 38: Middle East and Africa Anticancer Drugs Market Participants Presence (Intensity Mapping)
Table 39A: Competition Dashboard
Table 39B: Competition Dashboard
Table 39C: Competition Dashboard
Table 40: Anticancer Drugs Market Value (US$ Mn) 2013–2017 and Forecast 2018-2026 By Region
Table 41: Global Anticancer Drugs Market Value Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
Table 42: Global Anticancer Drugs Market Value Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indications
Table 43: Global Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channels
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized Version
Figure 01: Global Anticancer Drugs Market Value Share By Drug Class (2018 E)
Figure 02: Global Anticancer Drugs Market Value Share By Indications (2018 E)
Figure 03: Global Anticancer Drugs Market Value Share By Distribution Channel (2018 E)
Figure 04: Global Anticancer Drugs Market Value Share By Regions (2018 E)
Figure 05: New Cancer Drugs Approved Each Year
Figure 06: Growth of the Late Phase Oncology Pipeline, 2005-2015
Figure 07: The Global Late Phase Oncology Pipeline in 2015
Figure 08: Estimates Of National Expenditures For Cancer Care (In Billions Of Dollars) By Cancer Site And Year
Figure 09: Availability of 55 Oncology Medicines First Launched Globally 2012—2016
Figure 10: Number of FDA approved pharmaceuticals (2010-2017)
Figure 11: North America Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 12: North America Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 13: Canada Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 14: U.S. Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 15: Canada Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 16: U.S. Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 17: Hormonal Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 18: Cytotoxics Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 19: Hormonal Therapy Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 20: Cytotoxics Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 21: Targeted Therapy Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 22: Targeted Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 23: North America Anticancer Drugs Market Attractiveness Analysis By Country, 2018-2026
Figure 24: North America Anticancer Drugs Market Attractiveness Analysis By Indication, 2018-2026 (US$ Mn)
Figure 25: North America Anticancer Drugs Market Attractiveness Analysis By Distribution Channel, 2018-2026
Figure 26: North America Anticancer Drugs Market Attractiveness Analysis By Drug Class, 2018-2026
Figure 27: Latin Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 28: Latin Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 29: Mexico Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 30: Brazil Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 31: Mexico Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 32: Brazil Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 33: Rest of Latin America Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 34: Rest of Latin America Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 35: Hormonal Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 36: Cytotoxics Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 37: Hormonal Therapy Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 38: Cytotoxics Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 39: Targeted Therapy Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 40: Targeted Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 41: Latin America Anticancer Drugs Market Attractiveness Analysis By Country, 2018-2026
Figure 42: Latin America Anticancer Drugs Market Attractiveness Analysis By Indication, 2018-2026
Figure 43: Latin America Anticancer Drugs Market Attractiveness Analysis By Distribution Channel, 2018-2026
Figure 44: Latin America Anticancer Drugs Market Attractiveness Analysis By Drug Class, 2018-2026
Figure 45: Europe Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 46: Europe Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 47: Germany Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 48: U.K. Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 49: Germany Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 50: U.K. Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 51: Italy Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 52: France Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 53: Italy Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 54: France Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 55: Russia Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 56: Spain Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 57: Russia Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 58: Spain Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 59: Rest of Europe Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 60: Rest of Europe Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 61: Hormonal Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 62: Cytotoxics Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 63: Hormonal Therapy Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 64: Cytotoxics Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 65: Targeted Therapy Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 66: Targeted Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 67: Europe Anticancer Drugs Market Attractiveness Analysis By Country, 2018-2026
Figure 68: Europe Anticancer Drugs Market Attractiveness Analysis By Indication, 2018-2026
Figure 69: Europe Anticancer Drugs Market Attractiveness Analysis By Distribution Channel, 2018-2026
Figure 70: Europe Anticancer Drugs Market Attractiveness Analysis By Drug Class, 2018-2026
Figure 71: Asia Pacific Excluding Japan Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 72: Asia Pacific Excluding Japan Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 73: India Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 74: China Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 75: India Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 76: China Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 77: ASEAN Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 78: Australia and NZ Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 79: ASEAN Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 80: Australia and NZ Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 81: Rest of Asia Pacific Excluding Japan Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 82: Rest of Asia Pacific Excluding Japan Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 83: Hormonal Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 84: Cytotoxics Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 85: Hormonal Therapy Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 86: Cytotoxics Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 87: Targeted Therapy Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 88: Targeted Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 89: Asia Pacific Excluding Japan Anticancer Drugs Market Attractiveness Analysis By Country, 2018-2026
Figure 90: Asia Pacific Excluding Japan Anticancer Drugs Market Attractiveness Analysis By Indication, 2018-2026
Figure 91: Asia Pacific Excluding Japan Anticancer Drugs Market Attractiveness Analysis By Distribution Channel, 2018-2026
Figure 92: Asia Pacific Excluding Japan Anticancer Drugs Market Attractiveness Analysis By Drug Class, 2018-2026
Figure 93: Japan Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 94: Japan Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 95: Hormonal Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 96: Cytotoxics Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 97: Hormonal Therapy Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 98: Cytotoxics Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 99: Targeted Therapy Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 100: Targeted Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 101: Japan Anticancer Drugs Market Attractiveness Analysis By Drug Class, 2018-2026
Figure 102: Japan Anticancer Drugs Market Attractiveness Analysis By Indication, 2018-2026 (US$ Mn)
Figure 103: Japan Anticancer Drugs Market Attractiveness Analysis By Distribution Channel, 2018-2026
Figure 104: Middle East and Africa Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 105: Middle East and Africa Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 106: GCC Countries Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 107: South Africa Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 108: GCC Countries Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 109: South Africa Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 110: Rest of Middle East and Africa Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 111: Rest of Middle East and Africa Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 112: Hormonal Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 113: Cytotoxics Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 114: Hormonal Therapy Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 115: Cytotoxics Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 116: Targeted Therapy Drugs Market Value (US$ Mn) Analysis, 2013–2017
Figure 117: Targeted Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026
Figure 118: Middle East and Africa Anticancer Drugs Market Attractiveness Analysis By Country, 2018-2026
Figure 119: Middle East and Africa Anticancer Drugs Market Attractiveness Analysis By Indication, 2018-2026
Figure 120: Middle East and Africa Anticancer Drugs Market Attractiveness Analysis By Distribution Channel, 2018-2026
Figure 121: Middle East and Africa Anticancer Drugs Market Attractiveness Analysis By Drug Class, 2018-2026
Figure 122: Revenue Contribution by Tier Type
Figure 123: Global Anticancer Drugs Market Structure
Figure 124: Global Anticancer Drugs Market Share Analysis (%) By Region, 2018 & 2026
Figure 125: Global Anticancer Drugs Market Y-o-Y Growth (%) By Region, 2017–2026
Figure 126: Global Anticancer Drugs Market Attractiveness Analysis By Region, 2018–2026
Figure 127: Global Anticancer Drugs Market Share
Figure 128: Anticancer Drugs Market Y-o-Y Growth (%) By Drug Class, 2017–2026
Figure 129: Global Anticancer Drugs Market Attractiveness Analysis By Drug Class, 2018–2026
Figure 130: Global Anticancer Drugs Market Share
Figure 131: Anticancer Drugs Market Y-o-Y Growth (%) By Indications, 2017–2026
Figure 132: Global Anticancer Drugs Market Attractiveness Analysis By Indications, 2018–2026
Figure 133: Global Anticancer Drugs Market Share Analysis (%) By Distribution Channels, 2018 & 2026
Figure 134: Global Anticancer Drugs Market
Figure 135: Global Anticancer Drugs Market Attractiveness Analysis By Distribution Channels, 2018–2026
Figure 136: Global Anticancer Drugs Market Value Analysis and Forecast, 2017–2026 (US$ Mn)
Figure 137: Global Anticancer Drugs Market Absolute $ Opportunity (US$ Mn), 2017–2026
